Recently, a study reported that patients with FPLD3, harboring Arg308Pro (R308P) and Ala261Glu (A261E) PPARγ variants responded satisfactorily to synthetic PPARγ agonists (Agostini et al., 2018). Here, PPARG is linked to PPARG-related familial partial lipodystrophy.